ONCAlert | Upfront Therapy for mRCC
News
Genetic Profiling Suggests Rationale for Limited Response to Immunotherapy in Osteosarcoma
8:00 PM, Fri February 21, 2020
Novel Immunotherapy Agent ADXS-503 Plus Pembrolizumab Signals Promise in NSCLC
6:00 PM, Fri February 21, 2020
Conditioning Therapy With Iomab-B Improves Transplant Outcomes in Active AML
3:30 PM, Fri February 21, 2020
FDA Grants Priority Review for Selinexor in R/R Diffuse Large B-Cell Lymphoma
11:12 PM, Wed February 19, 2020
FDA Grants Breakthrough Therapy Designation To First-Line Enfortumab Vedotin/Pembrolizumab in Bladder Cancer
10:27 PM, Wed February 19, 2020
CLR 131 Elicits Notable Responses in Select Relapsed/Refractory B-cell Malignancies
9:30 PM, Wed February 19, 2020
FDA Grants Priority Review to Atezolizumab As Monotherapy in Advanced NSCLC
2:59 PM, Wed February 19, 2020
Plinabulin Combination Enhances Immune System and Prevents Neutropenia in Patients With Cancer
2:30 PM, Wed February 19, 2020
